Abstract
Hydroxyproline is a non-essential amino acid found in collagen and few other extracellular animal proteins. It’s two isomeric forms trans-4-hydroxy-L-proline and trans-3-hydroxy-L-proline play a crucial role in collagen synthesis and thermodynamic stability of the triple-helical conformation of collagen and associated tissues. Various abnormalities in hydroxyproline metabolism have been shown to play key roles in the pathophysiology and pathogenesis of different diseases. The elevated level of hydroxyproline is observed in several disorders, e.g., graft versus host disease, keloids, and vitiligo while its decreased level is a marker of poor wound-healing. This review explores the potential of using hydroxyproline as a biochemical marker to understand the pathogenesis, molecular pathophysiology and treatment of these diseases. The review concludes with an outlook on the scope and challenges in the clinical implementation of hydroxyproline as a biomarker.
Keywords: Hydroxyproline, collagen, biomarker, biomedical research, prolyl-4-hydroxylase.
Current Protein & Peptide Science
Title:Hydroxyproline: A Potential Biochemical Marker and Its Role in the Pathogenesis of Different Diseases
Volume: 17 Issue: 6
Author(s): Amit Kumar Srivastava, Piush Khare, Hemant Kumar Nagar, Navdeep Raghuwanshi and Rajnish Srivastava
Affiliation:
Keywords: Hydroxyproline, collagen, biomarker, biomedical research, prolyl-4-hydroxylase.
Abstract: Hydroxyproline is a non-essential amino acid found in collagen and few other extracellular animal proteins. It’s two isomeric forms trans-4-hydroxy-L-proline and trans-3-hydroxy-L-proline play a crucial role in collagen synthesis and thermodynamic stability of the triple-helical conformation of collagen and associated tissues. Various abnormalities in hydroxyproline metabolism have been shown to play key roles in the pathophysiology and pathogenesis of different diseases. The elevated level of hydroxyproline is observed in several disorders, e.g., graft versus host disease, keloids, and vitiligo while its decreased level is a marker of poor wound-healing. This review explores the potential of using hydroxyproline as a biochemical marker to understand the pathogenesis, molecular pathophysiology and treatment of these diseases. The review concludes with an outlook on the scope and challenges in the clinical implementation of hydroxyproline as a biomarker.
Export Options
About this article
Cite this article as:
Srivastava Kumar Amit, Khare Piush, Nagar Kumar Hemant, Raghuwanshi Navdeep and Srivastava Rajnish, Hydroxyproline: A Potential Biochemical Marker and Its Role in the Pathogenesis of Different Diseases, Current Protein & Peptide Science 2016; 17 (6) . https://dx.doi.org/10.2174/1389203717666151201192247
DOI https://dx.doi.org/10.2174/1389203717666151201192247 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research Meet Our Editorial Board Member
Current Alzheimer Research Glutamate Receptors in Microglia
CNS & Neurological Disorders - Drug Targets Advances in Extracorporeal Detoxification by MARS Dialysis in Patients with Liver Failure
Current Medicinal Chemistry The Role of FKBP5 in Mood Disorders: Action of FKBP5 on Steroid Hormone Receptors Leads to Questions About its Evolutionary Importance
CNS & Neurological Disorders - Drug Targets Use of the Bradykinin Agonist, Cereport as a Pharmacological Means of Increasing Drug Delivery to the CNS
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Quick-Release Bromocriptine for Treatment of Type 2 Diabetes
Current Drug Delivery Successful Screening of Large Encoded Combinatorial Libraries Leading to the Discovery of Novel p38 MAP Kinase Inhibitors
Combinatorial Chemistry & High Throughput Screening The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Targeting Gap Junctions: New Insights into the Treatment of Major Depressive Disorder
Current Medicinal Chemistry Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Current Pharmaceutical Design Editorial (Thematic Issue: Introduction to 'Beneficial Effects of Psychedelics with a Special Focus on Addictions')
Current Drug Abuse Reviews Neuropsychiatric Disturbances in Alzheimer’s Disease: What Have We Learned from Neuropathological Studies?
Current Alzheimer Research Association Between Chlamydia pneumoniae Antibodies and Lung Cancer: A Meta-Analysis
Current Respiratory Medicine Reviews Aminoalkylated Phenolic Chalcones: Investigation of Biological Effects on Acetylcholinesterase and Carbonic Anhydrase I and II as Potential Lead Enzyme Inhibitors
Letters in Drug Design & Discovery Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Software Packages for Quantitative Microarray-Based Gene Expression Analysis
Current Pharmaceutical Biotechnology A Pyridinium-substituted Analog of the TRH-like Tripeptide pGlu-Glu- Pro-NH2 and its Prodrugs as Central Nervous System Agents
Medicinal Chemistry